[Development of monoclonal antibodies to human tumor markers].
The development of hybridoma technology has provided the possibility of preparing unlimited amounts of highly specific and homogeneous monoclonal antibodies thus eliminating many of the disadvantages with conventional antisera and rekindling interest in the application of immunodiagnostic and immunotherapeutic approaches to human cancer. Several reports, including our own of monoclonal antibodies to tumor-associated antigens expressed by solid tumors including gastric, colorectal, lung and other various carcinomas, were reviewed from the viewpoint of tumor markers.